![Raphael Clynes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Raphael Clynes formerly worked at Circio Holding ASA, as Director from 2022 to 2023 and Xencor, Inc., as Vice President-Translational Biology from 2017 to 2024.
Dr. Clynes received his undergraduate degree from Massachusetts Institute of Technology and doctorate degree from Stony Brook University.
Eerdere bekende functies van Raphael Clynes
| Bedrijven | Functie | Einde |
|---|---|---|
| XENCOR, INC. | Corporate Officer/Principal | 01-01-2024 |
| CIRCIO HOLDING ASA | Directeur/Bestuurslid | 17-10-2023 |
Opleiding van Raphael Clynes
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
12
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Stony Brook University
 Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Circio Holding ASA
 Circio Holding ASA BiotechnologyHealth Technology Develops active immunotherapy cancer vaccines | Health Technology |
